Columbia Laboratories Demonstrates Commitment to Reproductive Health as Sapphire Sponsor of Pacific Coast Reproductive Society Annual Meeting.

LIVINGSTON, N.J. -- Columbia Laboratories, Inc. (NASDAQ: CBRX) is further demonstrating its commitment to infertility specialists and patients by serving as a sapphire sponsor for the 56th Annual Meeting of the Pacific Coast Reproductive Society.

This unique meeting includes scientific presentations by thought leaders in infertility and reproductive medicine and interactive learning sessions on a full range of reproductive health issues. It is being held April 9-13, 2008, at the Rancho las Palmas Resort and Spa in Rancho Mirage, California.

"Columbia Laboratories is delighted to be a sapphire sponsor of the Pacific Coast Reproductive Health Society annual meeting," said Robert S. Mills, president and chief executive officer. "Our company is fully committed to helping advance the understanding and treatment of reproductive disorders, providing educational opportunities for infertility specialists and clinicians, and supporting our patients as they navigate the pathway to parenthood."

Columbia is expanding its ongoing educational support and services to provide clinicians and patients the most current information regarding a woman's reproductive cycle, particularly the luteal phase, and the role of progesterone in preparing a woman's body for pregnancy and helping maintain that pregnancy.

Columbia recently launched a new website, www.crinoneusa.com, to educate women about the role of progesterone in fertility and pregnancy; it features clinical data on progesterone vaginal gel for healthcare providers.

About Progesterone and Luteal Phase Support

Progesterone is a naturally-occurring hormone that creates a healthy environment in a woman's uterus where a fertilized egg can implant and grow into a healthy baby. Most women undergoing infertility treatment need supplemental progesterone to help prepare the uterus for implantation and support fetal development during the first trimester.

Before ovulation, progesterone levels in a woman's body are relatively low. These levels rise after ovulation during the latter part of a woman's menstrual cycle, which is called the luteal phase, and ends with either pregnancy or menstruation, when the uterus sheds its lining. During pregnancy, progesterone helps maintain the lining of the uterus, providing necessary nutrients to support and nurture the fertilized egg.

About CRINONE([R]) 8%

CRINONE([R]) 8% was the first FDA-approved natural progesterone for progesterone supplementation or replacement as part of Assisted Reproductive Technology (ART) treatment for infertile women with progesterone deficiency, and is the only once a day treatment. CRINONE 8% is safe for use during pregnancy, and has been safely used for a decade by tens of thousands of women globally to help sustain pregnancy in the first trimester. Its unique bioadhesive delivery system provides controlled and sustained release of progesterone directly where it is needed. For more information, please visit www.crinoneusa.com.

The most common side effects of CRINONE 8% include breast enlargement, constipation, somnolence, nausea, headache, and perineal pain. CRINONE 8% is contraindicated in patients with active thrombophlebitis or thromboembolic disorders, or a history of hormone-associated thrombophlebitis or thromboembolic disorders, missed abortion, undiagnosed vaginal bleeding, liver dysfunction or disease, and known or suspected malignancy of the breast or genital organs.

CRINONE([R]) is a registered trademark of Columbia Laboratories, Inc.

About Columbia Laboratories

Columbia Laboratories, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the women's healthcare and endocrinology markets that use its novel bioadhesive drug delivery technology. Columbia markets CRINONE([R]) 8% (progesterone gel) in the United States for progesterone supplementation as part of an ART treatment for infertile women with progesterone deficiency. For more information, please visit www.columbialabs.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements about Columbia Laboratories, Inc.'s expectations regarding the Company's strategic direction, prospects and future results, which statements are indicated by the words "will," "plan," "expect" and similar expressions. Such forward-looking statements are subject to certain risks and uncertainties; actual results may differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. Factors that might cause future results to differ include, but are not limited to the successful marketing of CRINONE([R]) 8% (progesterone gel) in the U.S.; the timely and successful development of new products; the impact of competitive products and pricing; competitive economic and regulatory factors in the pharmaceutical and healthcare industry; general economic conditions; and other risks and uncertainties that may be detailed, from time-to-time, in Columbia's reports filed with the Securities and Exchange Commission. Columbia Laboratories undertakes no obligation to publicly update any forward-looking statements.